← All companies
RAPP
Rapport Therapeutics, Inc.
$40.79
-1.99 -4.65%
Key statistics
from XBRL data in SEC filingsMarket cap
$1.95B
Revenue (TTM)
—
Net income (TTM)
-$107M
EPS (TTM)
$-2.60
P/E ratio
—
Dividend yield
—
Free cash flow
-$88.1M
Cash
$78.1M
Total assets
$498M
Gross margin
—
52-week range
$13.62 – $44.28
Recent SEC filings
40 most recentAnnual, quarterly & current reports
8-K
Shareholder vote results
Jun 10, 2026
10-Q
Quarter ended 2026-03-31
May 7, 2026
8-K
Results of operations (earnings release)
May 7, 2026
8-K
Regulation FD disclosure; Other events
Apr 21, 2026
10-K
Fiscal year ended 2025-12-31
Mar 10, 2026
8-K
Results of operations (earnings release)
Mar 10, 2026
8-K
Other events
Jan 7, 2026
8-K
Regulation FD disclosure; Other events
Jan 7, 2026
10-Q
Quarter ended 2025-09-30
Nov 6, 2025
8-K
Results of operations (earnings release)
Nov 6, 2025
8-K
Entered a material agreement
Sep 10, 2025
8-K
Other events
Sep 8, 2025
8-K
Regulation FD disclosure; Other events
Sep 8, 2025
10-Q
Quarter ended 2025-06-30
Aug 7, 2025
8-K
Results of operations (earnings release); Regulation FD disclosure
Aug 7, 2025
8-K
Shareholder vote results
Jun 18, 2025
8-K
Regulation FD disclosure; Other events
Jun 2, 2025
10-Q
Quarter ended 2025-03-31
May 8, 2025
8-K
Results of operations (earnings release)
May 8, 2025
10-K
Fiscal year ended 2024-12-31
Mar 11, 2025
8-K
Results of operations (earnings release)
Mar 11, 2025
8-K
Regulation FD disclosure; Other events
Mar 3, 2025
8-K
Regulation FD disclosure; Other events
Jan 10, 2025
10-Q
Quarter ended 2024-09-30
Nov 7, 2024
8-K
Results of operations (earnings release)
Nov 7, 2024
10-Q
Quarter ended 2024-06-30
Aug 8, 2024
8-K
Results of operations (earnings release)
Aug 8, 2024
8-K
Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws
Jun 10, 2024
Other filings
4
Jul 29, 2026
4
Jul 15, 2026
4
Jul 1, 2026
4
Jul 1, 2026
144
Jun 30, 2026
144
Jun 29, 2026
4
Jun 10, 2026
4
Jun 10, 2026
4
Jun 10, 2026
4
Jun 10, 2026
4
Jun 10, 2026
4
Jun 10, 2026